IP Library Granted Patent US 10,617,460
Granted Patent B2
US 10,617,460 · App. 16/563,128 · Granted Apr 14, 2020

Neuromodulation for metabolic conditions or syndromes

Inventors: Bobak Robert Azamian (Newport Coast, CA); Jonathan Allen Coe (Menlo Park, CA); Scott Bradley Vafai (Boston, MA)
Assignee: Metavention, Inc.
A61B18/02A61B17/00A61B17/00234A61B17/32A61B18/04A61B18/06A61B18/1492A61B18/1815A61B18/20A61B18/24A61K9/0019A61K31/045A61K31/05A61K31/395A61K33/30A61K45/06A61M5/14A61N1/0551A61N5/00A61N7/00A61B2017/00318A61B2017/32007A61B2017/320069A61B2018/0022A61B2018/00023A61B2018/00214A61B2018/00404A61B2018/00434A61B2018/00529A61B2018/00577A61B2018/00732A61B2018/00791A61B2018/00839A61B2018/00994A61B2018/0212A61B2018/048A61B2018/1861A61N7/022
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,617,460
App. No.
16/563,128
Granted
Apr 14, 2020
Kind
B2
Abstract

According to some embodiments, a method of treating a subject having diabetes or symptoms associated with diabetes is provided. The method includes delivering a neuromodulation catheter within a vessel (e.g., hepatic artery) having surrounding nerves that innervate the liver (e.g., sympathetic nerves of the hepatic plexus). The method may also include modulating (e.g., disrupting, ablating, stimulating) the nerves by mechanical compression, energy delivery, or fluid delivery.

Claims (56)

1. A method of treating diabetes or other disease, disorder, or symptoms related to metabolic conditions, the method comprising:

inserting an energy delivery device within a common hepatic artery of a subject;

causing energy to be delivered by the energy delivery device to nerves innervating at least a first organ clinically relevant to diabetes or other related metabolic conditions, the first organ including a liver,

wherein the energy is sufficient to ablate the nerves innervating at least the first organ;

positioning the energy delivery device within a second artery in order to target nerves innervating at least a second organ clinically relevant to diabetes or other related metabolic conditions;

causing energy to be delivered by the energy delivery device to the nerves innervating at least the second organ,

wherein the energy is sufficient to ablate the nerves innervating at least the second organ, wherein the second organ is selected from the group consisting of: a pancreas, a small intestine, and a kidney.

2. The method of claim 1 :

wherein the nerves innervating at least the first organ comprise sympathetic nerves of a hepatic plexus surrounding the common hepatic artery;

wherein the nerves innervating at least the second organ comprise sympathetic nerves surrounding the second artery;

wherein the energy delivery device comprises a radiofrequency ablation catheter comprising multiple electrodes coupled to an expandable structure,

wherein the expandable structure is configured to be expanded using cooling fluid,

wherein the energy has a frequency of between 100 kHz and 2.5 MHz, and

wherein the multiple electrodes are configured to function as monopolar electrodes.

3. The method of claim 1 , wherein the second artery is selected from the group consisting of: a gastroduodenal artery, a gastric artery, a splenic artery, a superior mesenteric artery, and an inferior mesenteric artery.

4. The method of claim 1 , wherein the other related metabolic conditions are selected from the group consisting of: diabetes mellitus, diabetes insipidus, non-alcoholic fatty liver disease, and metabolic syndromes.

5. The method of claim 1 , wherein the other related metabolic conditions are selected from the group consisting of: non-alcoholic steatohepatitis, thyroid disease, obesity, hypertension, hyperglycemia, and hyperlipidemia.

6. A method of treating diabetes or other disease, disorder, or symptoms related to metabolic conditions, the method comprising:

inserting at least one energy delivery device within a subject;

positioning the at least one energy delivery device at a first location sufficient to deliver energy to nerves innervating at least a first organ that affects metabolism of the subject, the first organ including a liver,

causing the energy to be delivered using the at least one energy delivery device to the nerves innervating at least the first organ;

wherein the energy is sufficient to ablate the nerves innervating at least the first organ;

positioning the at least one energy delivery device at a second location sufficient to deliver energy to nerves innervating at least a second organ that affects metabolism of the subject;

causing the energy to be delivered by the at least one energy delivery device to the nerves innervating at least the second organ,

wherein the energy is sufficient to ablate the nerves innervating at least the second organ,

wherein the second organ is selected from the group consisting of: a pancreas, a small intestine, and a kidney.

7. The method of claim 6 :

wherein the nerves innervating at least the first organ comprise sympathetic nerves of a hepatic plexus surrounding a common hepatic artery;

wherein the nerves innervating at least the second organ comprise sympathetic nerves;

wherein the at least one energy delivery device comprises a radiofrequency ablation catheter comprising multiple electrodes coupled to an expandable structure,

wherein the expandable structure is configured to be expanded using cooling fluid,

wherein the energy has a frequency of between 100 kHz and 2.5 MHz, and

wherein the multiple electrodes are configured to function as monopolar electrodes.

8. The method of claim 6 , wherein the second location is a location within or adjacent an artery selected from the group consisting of: a gastroduodenal artery, a gastric artery, a splenic artery, a superior mesenteric artery, and an inferior mesenteric artery.

9. The method of claim 6 , wherein the other disease, disorder, or symptoms are selected from the group consisting of: diabetes mellitus, diabetes insipidus, non-alcoholic fatty liver disease, metabolic syndromes, and elevated blood glucose concentration.

10. The method of claim 6 , wherein the other disease, disorder, or symptoms are selected from the group consisting of: non-alcoholic steatohepatitis, thyroid disease, obesity, hypertension, hyperglycemia, and hyperlipidemia.

11. The method of claim 6 , wherein the at least one energy delivery device is configured to effect ablation of the nerves using one or more of the following modalities: radiofrequency, focused ultrasound, microwave, and cryoablation.

12. The method of claim 6 , wherein the step of positioning the at least one energy delivery device at a second location sufficient to deliver energy to nerves innervating at least the second organ that affects metabolism of the subject comprises intravascularly advancing a distal portion of the at least one energy delivery device to a location within vasculature sufficient to ablate nerves of at least one of: a splenic plexus, a renal plexus, a suprarenal plexus, a superior mesenteric plexus, and a celiac plexus.

13. The method of claim 6 , wherein the at least one energy delivery device consists of a single energy delivery device.

14. The method of claim 6 , wherein the at least one energy delivery device comprises a plurality of energy delivery devices.

15. A method of affecting one or more metabolic conditions, diseases or disorders of a subject, the method comprising:

delivering energy to nerves innervating a first metabolic organ of the subject from a first intravascular location;

wherein the energy is sufficient to ablate the nerves innervating the first metabolic organ;

delivering energy to nerves innervating a second metabolic organ of the subject from a second intravascular location,

wherein the energy is sufficient to ablate the nerves innervating the second metabolic organ,

wherein the first metabolic organ includes a liver, and wherein the second metabolic organ is selected from the group consisting of: a pancreas, a stomach, a kidney, and a small intestine.

16. The method of claim 15 , wherein the nerves innervating the first metabolic organ comprise sympathetic nerves of a hepatic plexus surrounding a common hepatic artery;

wherein the nerves innervating the second organ comprise sympathetic nerves;

wherein the energy is caused to be delivered by a radiofrequency ablation catheter comprising multiple electrodes coupled to an expandable structure,

wherein the expandable structure is configured to be expanded using cooling fluid,

wherein the energy has a frequency of between 100 kHz and 2.5 MHz, and

wherein the multiple electrodes are configured to function as monopolar electrodes.

17. The method of claim 15 , wherein the step of delivering energy to nerves innervating the first metabolic organ comprises intravascularly advancing a distal portion of an energy delivery device within a common hepatic artery, and wherein the step of delivering energy to nerves innervating the first metabolic organ and the step of delivering energy to nerves innervating the second metabolic organ are performed sequentially by the energy delivery device.

18. The method of claim 15 , wherein the step of delivering energy to nerves innervating the first metabolic organ comprises intravascularly advancing a distal portion of a first energy delivery device within a common hepatic artery, and wherein the step of delivering energy to nerves innervating the second metabolic organ comprises intravascularly advancing a distal portion of a second energy delivery device within a second artery from which the nerves innervating the second metabolic organ can be ablated by delivering energy using the second energy delivery device.

19. The method of claim 15 , further comprising delivering energy to nerves innervating a third metabolic organ, wherein the third metabolic organ is selected from the group consisting of: a pancreas, a stomach, a kidney, and a small intestine.

20. The method of claim 15 , wherein a modality of the energy comprises one or more of: radiofrequency, ultrasound, microwave, and cryoablation.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 21, 2023
From: METAVENTION, INC.
To: MEDTRONIC IRELAND MANUFACTURING UNLIMITED COMPANY
Reel/Frame 064987/0161 →
RELEASE OF SECURITY INTEREST Recorded Aug 22, 2023
From: CUSTOMERS BANK (SUCCESSOR IN INTEREST TO SIGNATURE BANK)
To: METAVENTION, INC.
Reel/Frame 064670/0039 →
SECURITY INTEREST Recorded Jan 11, 2023
From: METAVENTION, INC.
To: RVLHC II, LLC, AS COLLATERAL AGENT
Reel/Frame 062349/0859 →
SECURITY INTEREST Recorded Oct 31, 2022
From: METAVENTION, INC.
To: RVLHC II, LLC, AS COLLATERAL AGENT
Reel/Frame 061602/0249 →
SECURITY INTEREST Recorded Oct 7, 2022
From: METAVENTION, INC.
To: SIGNATURE BANK
Reel/Frame 061341/0724 →
SECURITY INTEREST Recorded Jun 29, 2022
From: METAVENTION, INC.
To: RVLHC II, LLC, AS COLLATERAL AGENT
Reel/Frame 060358/0417 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 1, 2022
From: AZAMIAN, BOBAK ROBERT; COE, JONATHAN ALLEN; VAFAI, SCOTT BRADLEY
To: METAVENTION, INC.
Reel/Frame 059137/0742 →
Continuity (8)
Continuation 16123308 · Sep 6, 2018
Continuation 15159616 · May 19, 2016
Continuation 14870861 · Sep 30, 2015
Continuation 14076008 · Nov 8, 2013
Continuation 13789509 · Mar 7, 2013
Continuation PCTUS2012068630 · Dec 7, 2012
Provisional Application 61568843 · Dec 9, 2011
Related Publication 20190388132A1 · Dec 26, 2019
Cited By (3)
US 12,408,974 US 12,478,806 US 12,539,167